IB ACQUISITION CORP (IBAC) Fundamental Analysis & Valuation

NASDAQ:IBAC • US44934N1081

Current stock price

10.8 USD
+0.04 (+0.37%)
Last:

This IBAC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. IBAC Profitability Analysis

1.1 Basic Checks

  • IBAC had positive earnings in the past year.
  • In the past year IBAC has reported a negative cash flow from operations.
IBAC Yearly Net Income VS EBIT VS OCF VS FCFIBAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 0 1M -1M 2M 3M

1.2 Ratios

Industry RankSector Rank
ROA 14.94%
ROE 16.07%
ROIC N/A
ROA(3y)2.86%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBAC Yearly ROA, ROE, ROICIBAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 0 50 100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IBAC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBAC Yearly Profit, Operating, Gross MarginsIBAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. IBAC Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, IBAC has less shares outstanding
  • There is no outstanding debt for IBAC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IBAC Yearly Shares OutstandingIBAC Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 5M 10M 15M
IBAC Yearly Total Debt VS Total AssetsIBAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • IBAC has an Altman-Z score of 31.60. This indicates that IBAC is financially healthy and has little risk of bankruptcy at the moment.
  • There is no outstanding debt for IBAC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 31.6
ROIC/WACCN/A
WACCN/A
IBAC Yearly LT Debt VS Equity VS FCFIBAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 0.31 indicates that IBAC may have some problems paying its short term obligations.
  • IBAC has a Quick Ratio of 0.31. This is a bad value and indicates that IBAC is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.31
Quick Ratio 0.31
IBAC Yearly Current Assets VS Current LiabilitesIBAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 500K 1M 1.5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. IBAC Growth Analysis

3.1 Past

  • IBAC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.98%.
EPS 1Y (TTM)-14.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-117.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. IBAC Valuation Analysis

4.1 Price/Earnings Ratio

  • IBAC is valuated quite expensively with a Price/Earnings ratio of 72.00.
  • When comparing the Price/Earnings ratio of IBAC to the average of the S&P500 Index (27.95), we can say IBAC is valued expensively.
Industry RankSector Rank
PE 72
Fwd PE N/A
IBAC Price Earnings VS Forward Price EarningsIBAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBAC Per share dataIBAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IBAC Dividend Analysis

5.1 Amount

  • IBAC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IBAC Fundamentals: All Metrics, Ratios and Statistics

IB ACQUISITION CORP

NASDAQ:IBAC (4/21/2026, 10:19:29 AM)

10.8

+0.04 (+0.37%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)02-11
Earnings (Next)05-13
Inst Owners32.19%
Inst Owner Change0%
Ins Owners17.71%
Ins Owner Change0%
Market Cap61.99M
Revenue(TTM)N/A
Net Income(TTM)2.45M
AnalystsN/A
Price TargetN/A
Short Float %0.16%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 72
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.07
P/tB 4.07
EV/EBITDA N/A
EPS(TTM)0.15
EY1.39%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS2.66
TBVpS2.66
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.99376 (-72.28%)
Profitability
Industry RankSector Rank
ROA 14.94%
ROE 16.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)2.86%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.31
Quick Ratio 0.31
Altman-Z 31.6
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-117.88%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.55%
OCF growth 3YN/A
OCF growth 5YN/A

IB ACQUISITION CORP / IBAC Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IB ACQUISITION CORP?

ChartMill assigns a fundamental rating of 1 / 10 to IBAC.


What is the valuation status for IBAC stock?

ChartMill assigns a valuation rating of 0 / 10 to IB ACQUISITION CORP (IBAC). This can be considered as Overvalued.


What is the profitability of IBAC stock?

IB ACQUISITION CORP (IBAC) has a profitability rating of 0 / 10.


What are the PE and PB ratios of IB ACQUISITION CORP (IBAC) stock?

The Price/Earnings (PE) ratio for IB ACQUISITION CORP (IBAC) is 72 and the Price/Book (PB) ratio is 4.07.


How financially healthy is IB ACQUISITION CORP?

The financial health rating of IB ACQUISITION CORP (IBAC) is 5 / 10.